There is no prediction that is worth the piece of paper it's written on. We need facts which we don't have.
What I do know is that the FDA has not improved the Copaxone landscape one iota with the approval of Glatopia. The FDA hasn't created a competitive landscape as desired. Actually, prices increased this year.
The reason for Generic's isn't too spread the wealth around, it's too create competition. A 3rd and 4th player will be needed and that's not lost on the FDA.
I wouldn't be surprised if someone else would be approved along with Momenta's 40mg.
Market Data 
Markets 
AI
